Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
Zhengye Biotechnology Holding Limited (ZYBT) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| TLPH Talphera, Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | 0.2× |
| INCR InterCure Ltd. compare | 8.8× |
| ZYBT Zhengye Biotechnology Holding Limited | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)